Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

The guidelines are a first-of-its-kind effort to establish recommendations for the medical management of HS in seven ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.

However, Pfizer's revenue guidance for 2025 doesn't look particularly exciting. The company expects its top line to come in ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Pfizer Inc. ( NYSE:PFE ) will increase its dividend from last year's comparable payment on the 7th of March to ...